A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.

Inclusion Criteria: * Have a histologically confirmed active CLE or SLE with cutaneous manifestations in the form of subacute cutaneous lupus erythematosus or/and discoid/chronic cutaneous lupus erythematosus at least 3 months and CLASI-A at least 8 or higher. * Participant has adequate intravenous infusion access per investigator's judgement * Willing to comply with study procedures including skin punch biopsies procedures. * Weight is greater than 40 kg and less than 130 kg. Exclusion Criteria: * Skin disorders other than CLE or SLE. * Active, severe lupus nephritis requiring treatment with cytotoxic agents or high-dose steroids. * Active severe central nervous system lupus requiring therapeutic intervention within 60 days of baseline. * Cancer or a history of cancer within 5 years of screening except adequately resected basal or squamous cell carcinoma of the skin, or carcinoma in situ of uterine cervix. * Known history of a major cardiovascular or cerebrovascular event within 24 months, pulmonary arterial hypertension, pulmonary embolism within 6 months of screening. * Have any autoimmune or inflammatory disease that would interfere with interpretation of test results or clinical assessments. * History of disseminated herpes zoster/simplex or recurrent herpes zoster. * Serious infection within 60 days of baseline or an active infection treated with oral antibiotics within 14 days of baseline. * Have evidence of active or latent infection of hepatitis B or C, known history of human immunodeficient virus (HIV) infection, or infected with Mycobacterium TB (active or latent TB) * Laboratory abnormalities that meet exclusion criteria at the Screening visit. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.